U.S. Markets open in 1 hr 36 mins
  • S&P Futures

    4,464.25
    -10.00 (-0.22%)
     
  • Dow Futures

    34,692.00
    -57.00 (-0.16%)
     
  • Nasdaq Futures

    15,489.50
    -28.25 (-0.18%)
     
  • Russell 2000 Futures

    2,225.50
    -7.70 (-0.34%)
     
  • Crude Oil

    72.17
    -0.44 (-0.61%)
     
  • Gold

    1,759.40
    +2.70 (+0.15%)
     
  • Silver

    22.89
    +0.14 (+0.61%)
     
  • EUR/USD

    1.1787
    +0.0015 (+0.1297%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    19.22
    +1.04 (+5.72%)
     
  • GBP/USD

    1.3797
    +0.0000 (+0.0028%)
     
  • USD/JPY

    109.9900
    +0.2720 (+0.2479%)
     
  • BTC-USD

    47,411.30
    -545.21 (-1.14%)
     
  • CMC Crypto 200

    1,202.71
    -30.58 (-2.48%)
     
  • FTSE 100

    7,024.74
    -2.74 (-0.04%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Real-World Data In Canada Shows AstraZeneca's COVID-19 Jab Is Over 80% Effective Against Variants

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine was 82% effective against hospitalization or death caused by the Beta/Gamma COVID-19 variants.

  • Dubbed Vaxzevria, the vaccine also showed a high level of effectiveness against the Delta (B.617.2, 'Indian') and Alpha (B.1.1.7, 'Kent') variants with 87% and 90% reduction in hospitalizations or deaths, respectively.

  • The data was published as a pre-print.

  • Follow-up time was insufficient to report on the vaccine's effectiveness after two doses; other studies have shown increased effectiveness following the indicated two-dose schedule.

  • Vaccine effectiveness against any symptomatic disease was 50% against the Beta/Gamma variants and 70% and 72% against the Delta and Alpha variants.

  • A Phase 1/2 trial carried out by the University of Oxford and the University of the Witwatersrand in January had shown limited efficacy against mild disease primarily due to the Beta variant.

  • The analysis included around 70,000 individuals who tested positive for the infection from December 2020 to May 2021 in Ontario, Canada, with 28,705 (6.8%) positive for non-variants and 40,828 (9.7%) positive for a variant of concern.

  • Price Action: AZN shares are up 0.14% at $58.04 during the premarket session on the last check Friday.

  • Photo by Wilfried Pohnke from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.